UK’s Real-World Evidence Expectations Still Not Clear To Industry
Executive Summary
Medtech companies looking to gain reimbursement for digital products in the UK are hindered by a confusing funding system and unclear real-world evidence requirements, but improvements should be easy to implement, trade association ABHI says.
You may also be interested in...
First Of Its Kind: UK Hospital To Apply For ADA-SCID Gene Therapy Approval
Great Ormond Street Hospital is piloting a new approach to gene therapy delivery in which it will submit a marketing authorization application to the UK regulator for a lentiviral gene therapy used to treat ADA-SCID, a rare disease.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.
EU Needs Market Access Improvements Beyond New HTA Regulation
While the EU Health Technology Assessment Regulation could reduce divergence in reimbursement decisions made across member states, many national-level HTA hurdles and challenges will remain, market access experts from EFPIA say.